Health CarePharmaceuticals & Biotechnology
  • Price (GBX)852.50
  • Today's Change20.50 / 2.46%
  • Shares traded846.86k
  • 1 Year change75.86%
  • Beta1.2673
Data delayed at least 20 minutes, as of Oct 20 2016 17:14 BST.
More ▼

Forecasts data is unavailable for this security.

Consensus recommendation

As of Oct 14, 2016, the consensus forecast amongst 2 polled investment analysts covering GW Pharmaceuticals plc advises investors to hold their position in the company. This has been the consensus forecast since the sentiment of investment analysts improved on Mar 14, 2016. The previous consensus forecast advised investors to sell their holdings in GW Pharmaceuticals plc.
  • 1yr ago
  • 3M ago
  • 2M ago
  • 1M ago
Select bar for recommendation details.

Share price forecast

The one analyst offering a 12 month price target expects the share price price of GW Pharmaceuticals plc to remain relatively unchanged over the next year.

Earnings history & estimates

On Dec 07, 2015, GW Pharmaceuticals plc reported 4th quarter 2015 losses of -0.047 per share. This result under-performed the breakeven expectation of the 3 analysts following the company but under-performed last year's 4th quarter results by -0.048.
The next earnings announcement is expected on Dec 05, 2016.
Average growth rate-83.16%
GW Pharmaceuticals plc reported annual 2015 losses of -0.181 per share on Dec 07, 2015.
The next earnings announcement from GW Pharmaceuticals plc is expected the week of Dec 05, 2016.
Average growth rate-100.63%
More ▼

Revenue history & estimates

GW Pharmaceuticals plc had 4th quarter 2015 revenues of 5.60m. This missed the 18.33m consensus estimate of the 3 analysts following the company. The same period last year the company did not report revenues.
Average growth rate-35.16%
GW Pharmaceuticals plc had revenues for the full year 2015 of 28.54m. This was 5.01% below the prior year's results.
Average growth rate-0.18%
More ▼
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.